Drug Profile
Anti-PCSK9 monoclonal antibody - Biocad
Latest Information Update: 24 Nov 2021
Price :
$50
*
At a glance
- Originator Biocad
- Class Cardiovascular therapies; Monoclonal antibodies
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Cardiovascular-disorders in Russia (Parenteral)
- 13 Apr 2018 Phase-I clinical trials in Cardiovascular disorders in Russia (Parenteral) (Biocad pipeline, April 2018)
- 27 Sep 2017 Preclinical trials in Cardiovascular disorders in Russia (Parenteral) before September 2017